Anti-Cancer Drug Design

Characterization of anticancer agents by their growth inhibitory activity and relationships to mechanism of action and structure
pp. 79-98(20)
Authors: Keskin O.; Bahar I.; Jernigan R.; Beutler J.; Shoemaker R.; Sausville E.; Covell D.

Synthesis and antitumor cytotoxicity evaluation of pyrido[4,3,2-de]quinolines and isoquinolino[6,5,4,3-cde]quinolines
pp. 99-108(10)
Authors: Ding Q.; Jia G.; Lown J.

Biological properties of 5,11-dimethyl-6H-pyrido[3,2-b]carbazoles: a new class of potent antitumor drugs
pp. 109-118(10)
Authors: Moinet-Hedin V.; Tabka T.; Poulain L.; Godard T.; Lechevrel M.; Saturnino C.; Lancelot J-C.; Le Talaël J-Y.; Gauduchon P.

Synthesis of new homochiral bispyrrolidines as potential DNA cross-linking antitumour agents
pp. 119-126(8)
Authors: Anderson F.; O'Hare C.; Hartley J.; Robins D.

Novobiocin-induced VP-16 accumulation and MRP expression in human leukemia and ovarian carcinoma cells
pp. 127-134(8)
Authors: Rappa G.; Murren J.; Johnson L-M.; Lorico A.; Sartorelli A.

The interaction of chalcones with tubulin
pp. 135-141(7)
Authors: Lawrence N.; McGown A.; Ducki S.; Hadfield J.

Photosensitizing properties of palladium-tetraphenylporphycene on cultured tumour cells
pp. 143-150(8)
Authors: Cañete M.; Ortiz A.; Juarranz A.; Villanuev A.; Nonell S.; Borrell J.; Teixidó J.; Stockert J.

In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines
pp. 151-160(10)
Authors: Johnstone S.; Gelmon K.; Mayer L.; Hancock R.; Bally M.